<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888758</url>
  </required_header>
  <id_info>
    <org_study_id>06042006</org_study_id>
    <nct_id>NCT00888758</nct_id>
  </id_info>
  <brief_title>Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction</brief_title>
  <acronym>ROBUST</acronym>
  <official_title>Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masaryk University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is:

        -  comparison of a safety and effectiveness of third generation DES (biolimus A9 and
           everolimus) in patients with STEMI treated by primary PCI with OCT guidance. A rate of 9
           month MACE (deaths, myocardial infarction, ischemia driven TLR) will be assessed in both
           groups.

      The secondary outcomes are a comparison of (using OCT):

        -  number of uncovered stent struts

        -  number of malapposed stents struts

        -  in-stent neointimal volume

        -  in-segment assessment of vessel wall response to DES
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this multicenter, prospective, randomized trial with a core lab analysis is to
      assess the safety and effectiveness (at 9-month follow-up) of third generation DES (biolimus
      A9 and everolimus) in patients with evolving STEMI with the OCT guidance (to optimize a stent
      implantation) A serial OCT analysis will be performed to assess the number of either
      uncovered or malaposed stents strut and a degree of in-stent neointimal hyperplasia.
      Furthermore, the in-segment vessel wall response to DES implantation will also be analysed.
      The goal is to enroll 400 patients (200 in each group) with OCT guidance in 100 patients in
      each group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare a safety and effectiveness of third generation DES (biolimus A9 and everolimus) in patients with STEMI treated by primary PCI with OCT guidance with assessment of a MACE's at 9 month follow-up</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of uncovered stent struts</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of malaposed stents struts</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-stent neointimal volume</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-segment assessment of vessel wall response to DES</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>biolimus A9</intervention_name>
    <description>200 patients with STEMI will be treated using Biomatrix stent.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>biolimus A9 eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>200 patients with STEMI will be treated with PROMUS DES.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>everolimus eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute STEMI within 12 hours from symptoms onset

          2. Native coronary disease with a lesion suitable for stenting

          3. Vessel size in between 2.5-3.75mm

          4. Patient is willing to provide written informed consent

          5. Male or female patients between 18-85 years of age

        Exclusion Criteria:

          1. Significant left main disease

          2. Killip class IV

          3. Known allergy to aspirin and or clopidogrel/ticlopidine

          4. Recent bleeding (&lt;1month)

          5. Patient in anticoagulant therapy

          6. No suitable coronary anatomy for OCT scan (ostial lesion, very distal or large vessel
             /&gt;3.75mm in diameter/)

          7. Pregnancy

          8. Severe liver or renal disease (Cr&gt;2.0)

          9. Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Cervinka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krajska zdravotni a.s., Masarzk hospital Usti nad Labem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pavel Cervinka, MD,PhD</last_name>
    <phone>+420477117886</phone>
    <email>pavel.cervinka@mnul.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Masaryk hospital and University of JEP</name>
      <address>
        <city>Ústí nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pavel Cervinka, MD,PhD</last_name>
      <phone>+420477117886</phone>
      <email>pavel.cervinka@mnul.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Kala, MD,P hD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ladislav Pesl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>April 30, 2009</last_update_submitted>
  <last_update_submitted_qc>April 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Assoc. prof. Pavel Červinka, MD, PhD, FESC, FSCAI</name_title>
    <organization>Masaryk hospital and University of JEP Ústí nad Labem</organization>
  </responsible_party>
  <keyword>Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Umirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

